People · Operator
Named in public records as an officer, director or promoter · active 2017–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Prelude Therapeutics Inc | — | Biotechnology | Series C | $115.0M | $1.9B | 2017 |
Kelvin Neu at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kelvin Neu on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Bonita | 1 | 6 |
| Paul Friedman | 1 | 5 |
| Mardi C. Dier | 1 | 2 |
| Victor Sandor | 1 | 2 |
| David Mauro | 1 | 2 |
| Brian C. Piper | 1 | 1 |
| David C. Mauro | 1 | 1 |
| Andrew C. Combs | 1 | 1 |
| Peggy Scherle | 1 | 1 |
| Juan Luengo | 1 | 1 |
| Krishna Vaddi | 1 | 1 |
| Peggy C. Scherle | 1 | 1 |
| Christopher C. Pierce | 1 | 1 |
| Deborah C. Morosini | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.